Figure 1. DAZALS exploratory overall survival analysis at one-year – patients who received 300 mg of dazucorilant compared to ...

ROCKVILLE, MD, USA I June 5, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) today announced new positive interim data from the Phase ...

Results of the Phase II study CONFIDENCE demonstrate that simultaneous initiation of finerenone and an SGLT-2-inhibitor (SGLT-2i) led to significant reductions in urine albumin-to-creatinine ratio ...

SAN DIEGO, CA, USA I June 05, 2025 I Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology ...

BOSTON, MY, USA I June 5, 2025 I Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced the first patient has ...

Casma’s first-in-class TRPML1 agonist represents a new therapeutic approach for targeting lysosomal dysfunction in genetically driven neurodegenerative diseases ...

SOLANA BEACH, CA, USA I June 05, 2025 I Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling ...

Median overall survival (OS) from ateganosine (THIO) treatment extends to 17.8 months in latest data CHICAGO, IL, USA I June 05, 2025 I MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the ...

Company enters into option agreement with NeurOp to in-license novel GluN2B antagonists – Compounds include a highly potent and selective Phase 1-complete candidate and seven preclinical candidates – ...

Trial is expected to provide key insights on how paxalisib therapy can be combined with established immunotherapies and standard of care chemotherapy to ...

LENSai™ powered by HYFT® technology Identifies a single multi-factorial target conserved across all dengue serotypes.

I On May 30, 2025, Conjustar Biologics announced that it's EphA2 targeting PDC drug SC-102 has received Investigational New Drug (IND) approval ...